Determining the Smallest Worthwhile Effect of Exercise in Patients with Rheumatic Musculoskeletal Diseases – A Multinational DACH Benefit–Harm Trade-Off Study

Read full text Summarise with VIRAT
Authors: Jean‐Pascal Grenier
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Primary Objective: To estimate the smallest worthwhile effect (SWE) for supervised exercise therapy, expressed as percentage pain reduction (0–100%) in patients with Rheumatic Musculoskeletal Diseases (RMD). Secondary Objectives: To describe the distribution of SWE values (mean/median, IQR) and to investigate predictors of SWE including age, symptom severity, disease duration, prior treatment experience etc. Participants will be recruited from the Rheumatology Outpatient Department of the Clinical Division of Internal Medicine II at the Medical University of Innsbruck, as well as through national patient organizations in Austria, and via online advertisements. After providing written informed consent, participants will complete assessments of pain intensity using a Numeric Rating Scale (NRS) over the last 24 hours and last seven days, physical activity using the International Physical Activity Questionnaire – Short Form (IPAQ-SF), and fatigue using the Fatigue Assessment Scale (FAS). Routine demographic and clinical data—including age, sex/gender, body mass index, smoking status, education, occupation, comorbidities, medication, and disease duration—will also be recorded. Participants diagnosed with axial spondyloarthritis (axSpA) will additionally complete the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI), and the General Attitudes toward Strength Training Questionnaire (G-ASKQ-7) for a planned subanalysis in this specific patient subgroup. To estimate the smallest worthwhile effect (SWE) for non-pharmacological interventions, participants will receive standardized descriptions of three interventions: supervised exercise therapy (high-intensity resistance and aerobic training, twice weekly for 8–12 weeks) in a group-setting and in an one-on-one setting with a physiotherapist, and app-guided exercise and educational modules. Descriptions include the expected benefits, potential risks, burdens, and costs associated with each intervention. For each intervention, participants will first indicate whether it would be worthwhile if it resulted in complete pain relief. If they respond affirmatively, they will then specify the minimal improvement in pain they would require for the intervention to be worthwhile, measured as a percentage reduction in pain (0–100%). This study is conceptualized as an international, cross-sectional, benefit-harms trade-off study conducted in accordance with STROBE guidelines. Adults (≥18 years) with a diagnosed rheumatic musculoskeletal disease (RMD) according to disease-specific classification criteria, or a self-reported diagnosis of a rheumatic disease commonly associated with inflammatory arthritis (e.g., rheumatoid arthritis, psoriatic arthritis, sarcoidosis, Sjögren’s syndrome, systemic lupus erythematosus), who are willing and able to provide written informed consent in German, are eligible to participate. Patients will be excluded if they are unwilling or unable to provide consent, do not have a rheumatic diagnosis, or have exclusively chronic primary pain or osteoarthritis. No other exclusion criteria are applied, as the study involves only questionnaire-based assessments and clinical vignettes. All participants will be informed about study procedures and provide written informed consent. The study has been approved by the Ethics Committee of the Medical University of Innsbruck. 100-200 patients for the main analysis. If at least 85 patients with axial spondyloarthritis participate we will perform a sub-analysis in this specific patient population. Cross-sectional study: one to three years, depending on recruitment status eventually less. No follow-ups are planned. PI: Ass.in Prof.in Priv.Doz.in Dr.in C. Duftner, PhD (University Clinic of Innsbruck, Department of Internal Medicine II, Innsbruck, Austria) Study coordination: Dr. Jean-Pascal Grenier, MSc (University Clinic of Innsbruck, Department of Internal Medicine II, Innsbruck, Austria)

Fields of Study & Subjects

Musculoskeletal pain and rehabilitation Spondyloarthritis Studies and Treatments Physical Activity and Health

Publication details

Publication date
1 January 2026
Language
EN
Document type
Preprint